



Zerviate™ (cetirizine) – New drug approval

- On May 31, 2017, [Nicox announced](#) the FDA approval of [Zerviate \(cetirizine\)](#) ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis.
- Allergic conjunctivitis causes eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light. Approximately 75 million people in the U.S. suffer from allergic conjunctivitis.
- Cetirizine is a second generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites to reduce swelling, itching and vasodilation.
- Cetirizine is also available generically over the counter as an [oral solution](#), [oral tablets](#), [oral chewable tablets](#), [oral capsules](#), and [in combination with pseudoephedrine](#).
- The efficacy of Zerviate was demonstrated in 3 placebo-controlled conjunctival allergen challenge (CAC) trials in patients with a history of allergic conjunctivitis. Patients were evaluated with an ocular itching severity score ranging from 0 (no itching) to 4 (incapacitating itch) at several time points after CAC administration.
 - Patients treated with Zerviate demonstrated statistically and clinically significantly less ocular itching vs. vehicle at 15 minutes and 8 hours after treatment.
- Warnings and precautions of Zerviate include contamination of tip and solution and contact lens wear.
- The most common adverse events (1 – 7%) with Zerviate use were ocular hyperemia, instillation site pain, and visual acuity reduced.
- The recommended dose of Zerviate is one drop in each affected eye twice daily (approximately 8 hours apart).
- Nicox's launch plans for Zerviate are pending. Zerviate will be available as a 0.24% ophthalmic solution in 7.5 mL and 10 mL bottles.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.